Codman Neuro has launched the Enterprise 2 vascular reconstruction device in Europe. The Enterprise 2 system is the latest generation of the company’s self-expanding stent and delivery system used to treat wide-necked intracranial aneurysms and to help maintain the position of endovascular coils. Codman Neuro is a part of the DePuy Synthes Companies of Johnson & Johnson.
Jan-Hendrik Buhk, from University Medical Centre, Hamburg Eppendorf, was the first interventional neuro-radiologist in EMEA to use the technology. “The Enterprise 2 System provided me with predictable positioning, intraoperative control and stability once in place, and fully met my expectations of a remodelling stent,” said Buhk.
According to Codman Neuro, the Enterprise 2 System is designed to improve vessel wall conformability in tortuous anatomy, while maintaining its ability to provide a stable structure at the neck of an aneurysm, securing the placement of coils and maintaining blood flow through the artery. Furthermore, the stent is more visible under fluoroscopy than the previous device and comes with device enhancements that make it easier for physicians to deploy during the procedure.
“At Codman Neuro, we recognise the critical need for neurovascular products that more effectively target wide-neck aneurysms,” said Christoph Eigenmann, marketing director DePuy Synthes Spine and Codman Neuro EMEA. “We have made important design improvements to the Enterprise 2 system so that it better fits vascular anatomy, is more visible on X-Ray, and is more easily deployed.”
The Enterprise 2 system is intended for use with occlusive devices in the treatment of intracranial aneurysms. More than 80,000 patients worldwide have been treated for cerebral aneurysms with the first generation of the device, which has been available worldwide since 2006.
